Evidence map›Paper›PMID 31844807›Full record

ArticleKidney international reports2019

Pretransplant Levels of C-Reactive Protein, Soluble TNF Receptor-1, and CD38+HLADR+ CD8 T Cells Predict Risk of Allograft Rejection in HIV+ Kidney Transplant Recipients.

Jose F Camargo, Suresh Pallikkuth, Ilona Moroz, Yoichiro Natori, Maria L Alcaide, Allan Rodriguez, Giselle Guerra, George W Burke, Savita Pahwa

Open access · goldAbstract read
In one paragraph

Article in Kidney international reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Association between CD4BMC infectious diseases · 2021
    Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Jose F CamargoDivision of Infectious Diseases, University of Miami Miller School of Medicine, Miami, Florida, USA.
Suresh PallikkuthDepartment of Microbiology and Immunology, University of Miami Miller School of Medicine, Miami, Florida, USA.
Ilona MorozDivision of Infectious Diseases, University of Miami Miller School of Medicine, Miami, Florida, USA.
Yoichiro NatoriDivision of Infectious Diseases, University of Miami Miller School of Medicine, Miami, Florida, USA.
Maria L AlcaideDivision of Infectious Diseases, University of Miami Miller School of Medicine, Miami, Florida, USA.
Allan RodriguezDivision of Infectious Diseases, University of Miami Miller School of Medicine, Miami, Florida, USA.
Giselle GuerraMiami Transplant Institute, Miami, Florida, USA.
George W BurkeMiami Transplant Institute, Miami, Florida, USA.
Savita PahwaDepartment of Microbiology and Immunology, University of Miami Miller School of Medicine, Miami, Florida, USA.
University of Miami · USMiami Transplant Institute · US

Funding

University of Miami Developmental Center for AIDS Research (D-CFAR)P30AI073961 · NIAID · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI GWENDOLYN Barbara SCOTT · 2007 to 2026
$33.8M
NIAID NIH HHS P30 AI073961
6 · The paper itself

Abstract

introductionHIV-positive (HIV+) kidney transplant recipients exhibit a 2- to 3-fold increased risk of allograft rejection. Dysregulated immune activation in HIV infection persists despite successful antiretroviral therapy and is associated with non-AIDS morbidity, including renal disease. We hypothesized that the pathological levels of inflammation and immune activation associated with chronic HIV infection could have clinical utility in the prediction of rejection in HIV+ kidney recipients.

methodsProspective cohort study of 22 HIV-negative (HIV-; donor) to HIV+ (recipient) kidney transplant recipients who underwent biomarker assessment pretransplant and were subsequently followed for development of acute rejection. Plasma levels of markers of inflammation (soluble tumor necrosis factor receptor 1 [sTNF-R1] and C-reactive protein [CRP]) and microbial translocation (soluble CD14 and lipopolysaccharide) were measured by enzyme-linked immunosorbent assay or chromogenic endpoint assay. Levels of activated (CD38+HLADR+) CD4+ and CD8+ T cells, and T regulatory cells (CD4+CD25highFoxP3+) were measured by flow cytometry.

resultsAmong the biomarkers evaluated, only the pretransplant levels of sTNF-R1, CRP, and frequencies of CD38+HLADR+ CD8 T cells, were found to be at significantly higher levels among patients who experienced biopsy-proven acute rejection. Confirming our hypothesis, patients with high pretransplant levels of sTNF-R1 or activated CD8+ T cells had a significantly increased 200-day cumulative incidence of biopsy-proven acute rejection (0 vs. 38% for both;

conclusionBiomarker-based identification of HIV+ recipients at increased risk for rejection might facilitate individualized induction immunosuppression regimens in this vulnerable patient population.

Indexed as

C-reactive proteinHIVkidney transplantrejectionsTNF-R1T-cell activation

Identifiers

PMID31844807
PMCPMC6895601
OpenAlexW2969699642

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.